Fate Therapeutics Inc. (FATE)
NASDAQ: FATEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 1:42 PM ET
FATE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $250.42M
- EPS (TTM)
- -$1.05
- Dividend yield
- None
- 52-week range
- 0.95 – 3.23
- Day range
- 2.03 – 2.12
- Volume / Avg
- 671.32K / 1.89M
- Beta
- —
- Shares outstanding
- 119.82M
52-week range
FATE stock today
Fate Therapeutics (FATE) is trading at $2.09 on Oct 8, down 2.79% (-$0.06), versus the S&P 500's 0.63% decline. At this level, FATE sits in the middle of its 52-week range of $0.95 to $3.23: 35.3% below the high, set on Jul 13, 2026 and 120.0% above the low. FATE is up 119.4% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 54.7%.
Fate Therapeutics has posted a net loss over the last twelve months (EPS of -$1.05), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Fate Therapeutics
Company profileFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Bahram Valamehr M.B.A., Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 161
- IPO year
- 2013
- Website
- fatetherapeutics.com
Analyst forecast
ForecastConsensus (11 analysts)
buy
Avg. price target
$5.74+174.64%
- Strong buy 1
- Buy 4
- Hold 6
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
FATE news
All FATE newsFate Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LXEOLexeo Therapeutics Inc. | 3.15 | -4.98% | $258.17M | vs FATE |
| LCTXLineage Cell Therapeutics Inc. | 1.03 | +8.70% | $260.49M | vs FATE |
| PALIPalisade Bio Inc. | 1.43 | -3.38% | $249.21M | vs FATE |
| SABSSAB Biotherapeutics Inc. | 2.93 | +1.70% | $266.50M | vs FATE |
| STROSutro Biopharma Inc. | 16.08 | +9.69% | $266.63M | vs FATE |
| IKTInhibikase Therapeutics Inc. | 1.93 | -0.77% | $268.61M | vs FATE |
| IPSCCentury Therapeutics Inc. | 1.35 | +5.47% | $244.45M | vs FATE |
| XFORX4 Pharmaceuticals Inc. | 2.79 | -0.71% | $276.62M | vs FATE |
Indexes, lists and sector
Fate Therapeutics stock FAQ
What is Fate Therapeutics's stock price today?
FATE last traded at $2.09 as of Oct 8, 1:42 PM EDT, down 2.79% on the day. Prices are delayed at least 15 minutes.
Who is Fate Therapeutics's CEO?
Dr. Bahram Valamehr M.B.A., Ph.D. is the chief executive officer of Fate Therapeutics Inc., which has about 161 employees.
What is the FATE 52-week high?
The 52-week high for FATE is $3.23 and the 52-week low is $0.95. The stock is currently 35.3% below its high.